New kids on the block—step by step to an ideal HCV therapy-Reference-Cited by-同舟云学术

New kids on the block—step by step to an ideal HCV therapy

Published:2015-03 Issue:9973 Volume:385 Page:1050-1052
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Cornberg Markus,Manns Michael P

Publisher

Elsevier BV

Subject

General Medicine

Reference17 articles.

1. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting;Maasoumy;PLoS One,2013

2. Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease;Maasoumy;Eur J Gastroenterol Hepatol,2014

3. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study;Lawitz;Lancet,2014

4. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection;Sulkowski;N Engl J Med,2014

5. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study;Manns;Lancet,2014

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The curing regimens of HCV: A SWOT analysis;Antiviral Therapy;2022-04

2. Universo emocional de mujeres afectadas por hepatitis C: una aproximación hermenéutica;Enfermería Clínica;2019-07

3. The emotional universe of women affected by hepatitis C: A hermeneutic approach;Enfermería Clínica (English Edition);2019-07

4. Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy;Hepatic Medicine: Evidence and Research;2018-05

5. Evaluation of the biomarker candidate MFAP4 for non-invasive assessment of hepatic fibrosis in hepatitis C patients;Journal of Translational Medicine;2016-07-04